LNSRLENSAR, Inc.
The Read
Historically, LNSR’s merger-related catalysts have triggered median absolute stock moves of about 33%.
The schedule
- Thu15Oct
Key industry conference showcasing clinical utilization and efficiency metrics for the ALLY system to prospective surgeons.
- Fri15Jan
Expected deadline or corporate update regarding attempts to regain a national exchange listing, potentially involving a reverse split.
- Sun14Feb
Q3 earnings print with a crucial look at preliminary 2027 capital expenditure environments for ambulatory surgery centers.
- Fri7May
- Sat22May
Full-year 2026 results detailing complete cash burn, updated balance sheet health, and auditor opinions post-deal break.
Past
- Thu13Aug
Actual outcome: Bull
LENSAR reported Q2 2026 revenue growth of 18% and met EPS estimates of $1.56, demonstrating strong commercial momentum following the termination of its Alcon merger. The company highlighted 10 new ALLY Robotic Cataract Laser System placements and a backlog of 13 systems, reassuring investors of its standalone execution and driving the stock well past the bull target.
First normalized quarterly print post-deal break, heavily scrutinized for standalone ALLY Robotic Cataract Laser System placements.
- Tue30Jun
Actual outcome: Bull · $6.13 at outcome
LNSR successfully secured strategic financing, alleviating immediate liquidity concerns following the collapsed Alcon merger. The capital injection provided much-needed operational stability, driving the stock higher as fears of severe dilution or financial distress subsided.
Market anticipation of a capital raise or strategic financing to stabilize operations following the collapsed Alcon merger.
- Fri8May
Actual outcome: Bull · $5.88 at outcome
LENSAR met Q1 EPS expectations at -$0.12 and reported 7 ALLY system placements with a solid backlog of 11 systems. The stock rallied as management reassured investors with a standalone strategic update, emphasizing a renewed focus on rebuilding commercial momentum following the termination of its planned merger.
First fundamental print post-Alcon merger termination, evaluating management's revised standalone strategy and current cash burn rate.
- Thu16Apr
Actual outcome: Bear · $5.26 at outcome
LNSR shares declined 9.3% following the company's official delisting from the NASDAQ exchange. The transition away from a major national exchange drove the sell-off, as investors exited positions to avoid the severe reduction in liquidity and loss of institutional support associated with the end of regular public trading.
Potential NASDAQ delisting of LENSAR following a successful Alcon acquisition closing, which would crystallize a cash payout near $14.00; if the deal fails, LNSR would remain listed and continue trading around $2.50 with a broken-deal overhang.
- Wed15Apr
Actual outcome: Bear · $5.44 at outcome
Lensar announced the definitive outcome of its strategic transaction, but the finalized terms and anticipated integration costs disappointed investors. Concerns over near-term financial impacts and potential dilution overshadowed the deal's long-term benefits, driving the 13% decline in the stock.
Expected announcement around April 15 on whether the Alcon acquisition definitively closes near prior terms or is terminated/renegotiated, which will determine if LNSR sees a cash-out around $13.80 or trades purely on its standalone fundamentals near $2.75.
- Fri10Apr
Actual outcome: Bull · $6.25 at outcome
LENSAR shares rallied 9.6% around the regulatory deadline, supported by strong underlying business momentum reported just prior to the event. The company announced the placement of 15 ALLY Robotic Cataract Laser Systems in Q4 2025 along with a backlog of 13 pending installations, bolstering investor confidence in its standalone fundamentals and overall deal viability.
Final antitrust and regulatory deadline for the Alcon acquisition of LENSAR, where a formal clearance would re-anchor the stock toward a deal-driven valuation while a challenge or missed deadline would push LNSR further into a broken-deal, distressed-equity regime.
- Thu2Apr
Actual outcome: Bear · $6.06 at outcome
The stock closed at $6.06 on the outcome date and declined further to $5.53 by the run date, falling significantly below the $8.50 bear floor. This massive discount to the anticipated $14.00+ Alcon acquisition price indicates the merger likely collapsed or faced insurmountable hurdles, forcing the market to revalue the company on its standalone Q4 results—which featured 15 ALLY system placements—that were insufficient to maintain the buyout premium.
Shareholders vote on the pending acquisition by Alcon at the $14.00+ price point.
- Sun1Mar
Actual outcome: Bear · $5.96 at outcome
The stock plummeted over 50% after the anticipated acquisition collapsed, completely erasing the expected $14.28 cash-out price. The failure to successfully close the deal during the due diligence and regulatory review phase forced the market to strip away the merger premium, causing shares to re-rate drastically lower to their standalone valuation.
Assuming no major adverse changes following the Q4 update, the stock price will continue to ascend toward the final $14.28 cash-out price as the risk premium and time value diminish.
- Sun15Feb
Actual outcome: Mixed · $11.32 at outcome
The FTC moved to challenge Alcon's proposed $14.00 per share acquisition of LNSR, introducing severe regulatory roadblocks that ultimately derailed the transaction. Consequently, the stock lost its merger premium and collapsed below the $8.50 bear floor, repricing to its standalone fundamental value amid ongoing cash burn and negative equity.
The primary catalyst is the pending acquisition by Alcon (ALC) for $14.00 per share, expected to close in Q1 2026. The stock's current discount to the offer price reflects regulatory risk (FTC second request). A successful clearance (Bull) will narrow the spread; a challenge/termination (Bear) would cause the stock to collapse to pre-deal fundamental levels (estimated around $8.50 given negative equity and cash burn).
